Literature DB >> 3167144

The effect of diagnosis and age on the DST: a metaanalytic approach.

R P Sharma1, G N Pandey, P G Janicak, J Peterson, J E Comaty, J M Davis.   

Abstract

The authors present new data on the results of the pretreatment Dexamethasone Suppression Test (DST) in 164 drug-free inpatients, as well as on the effects of age on postdexamethasone cortisol values. Nonsuppression rates were 18% in schizophrenic patients (n = 44), versus 46% in patients with a major depression (n = 56). In addition, a significant correlation was found between age and the 4:00 PM postdexamethasone cortisol value among the depressed patients (r = 0.33). The authors then applied a metaanalysis to summarize 25 other studies that have addressed the schizophrenia/major depression dichotomy as it relates to the DST outcome. Nonsuppression rates were consistently different in schizophrenic patients (19%) when compared to patients with a major depression (51%) or normal controls (7%). These differences were highly significant as measured by the Mantel-Haenszel chi-square statistic. A metaanalysis applied to a series of correlations obtained from 14 other studies reporting an age/postdexamethasone cortisol relationship in affective patients indicated a modest, but significant correlation (r = 0.24) in a total of 1284 patients (p less than 1 x 10(-8)).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3167144     DOI: 10.1016/0006-3223(88)90166-7

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  7 in total

1.  Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone.

Authors:  Eric J Lenze; Tamara Hershey; John W Newcomer; Jordan F Karp; Daniel Blumberger; Jennifer Anger; Peter Doré; David Dixon
Journal:  Int J Geriatr Psychiatry       Date:  2014-03-14       Impact factor: 3.485

2.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

3.  Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine.

Authors:  Cornelius Schüle; Thomas Baghai; Peter Zwanzger; Robin Ella; Daniela Eser; Frank Padberg; Hans-Jürgen Möller; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2003-01-28       Impact factor: 4.530

4.  The biochemical womb of schizophrenia: A review.

Authors:  N Gaur; S Gautam; M Gaur; P Sharma; G Dadheech; S Mishra
Journal:  Indian J Clin Biochem       Date:  2008-12-20

5.  Possible association between interleukin-1β gene and schizophrenia in a Japanese population.

Authors:  Daimei Sasayama; Hiroaki Hori; Toshiya Teraishi; Kotaro Hattori; Miho Ota; Yoshimi Iijima; Masahiko Tatsumi; Teruhiko Higuchi; Naoji Amano; Hiroshi Kunugi
Journal:  Behav Brain Funct       Date:  2011-08-16       Impact factor: 3.759

6.  Revisiting the Dexamethasone Suppression Test in unipolar major depression: an exploratory study.

Authors:  Konstantinos N Fountoulakis; Xenia Gonda; Zoltan Rihmer; Costas Fokas; Apostolos Iacovides
Journal:  Ann Gen Psychiatry       Date:  2008-11-13       Impact factor: 3.455

7.  Bipolar Disorder is associated with the rs6971 polymorphism in the gene encoding 18 kDa Translocator Protein (TSPO).

Authors:  Alessandro Colasanti; David R Owen; Detelina Grozeva; Eugenii A Rabiner; Paul M Matthews; Nick Craddock; Allan H Young
Journal:  Psychoneuroendocrinology       Date:  2013-08-12       Impact factor: 4.905

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.